Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075500 | 0.95 | ALDH1A1 (0.37) | ALDH1A1LMNAADRB2TP53PKM | |
| SCHEMBL25569663 | 0.91 | ALDH1A1 (0.37) | ALDH1A1LMNAADRB2TP53PKM | |
| SCHEMBL25565751 | 0.84 | KDM4E (0.38) | ALDH1A1TP53PKMKDM4ESMN1; SMN2 | |
| SCHEMBL12542134 | 0.84 | MAPT (0.35) | LMNAADRB2TP53HRH3HTR1B | |
| SCHEMBL19502501 | 0.83 | SIGMAR1 (0.38) | ALDH1A1TP53PKMKDM4ESMN1; SMN2 | |
| SCHEMBL25565745 | 0.82 | HRH3 (0.36) | ALDH1A1LMNAADRB2HRH3KDM4E | |
| SCHEMBL12703408 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAADRB2HTR1BNR2E1 | |
| SCHEMBL25101936 | 0.81 | SIGMAR1 (0.39) | ALDH1A1 | |
| SCHEMBL25565770 | 0.80 | CHRM2 (0.37) | ALDH1A1KDM4E | |
| SCHEMBL24477365 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNAADRB2HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | ALDH1A1 3979/4885LMNA 72/4885ADRB2 4665/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | ALDH1A1 3422/4885LMNA 449/4885ADRB2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.